Monkeypox (Mpox) Diagnosis Market Set to Reach US$2.4 Billion by 2031, Driven by Advancements in Diagnostic Technologies and Rising Global Awareness

Overview of the Market

The Monkeypox (mpox) diagnosis market is witnessing rapid growth, driven by the increasing demand for accurate diagnostic solutions following the resurgence of the virus. The market is expected to grow from an estimated US$1.95 billion in 2024 to US$2.4 billion by 2031, with a compound annual growth rate (CAGR) of 4.4% during the forecast period. Monkeypox, a viral disease similar to smallpox but less severe, is transmitted from animals to humans. The resurgence of the disease, especially in 2022 and 2023, led to heightened global awareness and a significant increase in diagnostic demand. In 2022, for instance, the World Health Organization (WHO) reported a surge in monkeypox cases worldwide, which in turn increased the focus on diagnostic procedures and tools for effective containment.

Get a Sample PDF Brochure of the Report (Use Corporate Email ID for a Quick Response): https://www.persistencemarketresearch.com/samples/34755

Several growth drivers are contributing to the expansion of the mpox diagnosis market, such as advancements in molecular diagnostic technologies, the integration of monkeypox testing into broader infectious disease panels, and the expansion of point-of-care testing (POCT) facilities. Among the various diagnostic tests available, molecular tests dominate the market, with a substantial share in 2024. Additionally, the skin lesion specimen segment, being the most reliable sample for diagnosis, holds a significant portion of the market share.

North America is expected to lead the global market, accounting for approximately 41% of the market share in 2024. The region's dominance can be attributed to the substantial investments in medical research and development, a well-established healthcare system, and high demand for diagnostic services. The continued growth in North America is further bolstered by rising awareness about vaccination and preventive measures, contributing to increased demand for monkeypox testing and diagnostics.

Key Highlights from the Report

✦ The monkeypox (mpox) diagnosis market is projected to grow at a CAGR of 4.4% from 2024 to 2031.
✦ Point-of-care testing (POCT) expansion is driving the overall market growth.
✦ Increased global awareness and surveillance are accelerating the demand for monkeypox diagnostics.
✦ Technological advancements in diagnostic tools contribute to market revenue generation.
✦ The molecular test segment dominates the diagnostic tests market, with a 55% market share in 2024.
✦ North America holds the largest share of the market, accounting for 41% of the market share in 2024.

Market Segmentation

The monkeypox diagnosis market can be segmented based on various factors such as diagnostic test type, sample type, end-user, and region.

Diagnostic Test Type:

Molecular Test: The molecular test segment is the dominant category within the market. It accounted for 55% of the total market share in 2024. Molecular diagnostic tests, like PCR (Polymerase Chain Reaction), are widely used due to their precision, accuracy, and ability to detect the genetic material of the virus. These tests are essential in clinical settings where reliable results are required for disease management.

Antigen Detection Test: While not as accurate as molecular tests, antigen detection tests are gaining traction due to their rapid results and lower cost. They are primarily used in point-of-care testing situations where speed is crucial.

Sample Type:

Skin Lesion Specimen: Skin lesion specimens are expected to hold a dominant market share of 63% in 2024. This is because monkeypox manifests with distinctive rashes and pustules, which are easy to identify and are the most reliable source for virus detection. PCR tests, applied to these skin lesion specimens, are highly effective for diagnosing monkeypox.

Urine and Whole Blood Samples: Though less common, urine and blood samples are occasionally used in diagnosing monkeypox, especially in advanced cases where lesions are absent or not visible.

End-User:

Hospitals: As primary centers for diagnosing infectious diseases, hospitals hold a significant share in the market. Advanced diagnostic facilities, such as PCR labs, and the need for effective disease management strategies fuel the demand for monkeypox testing in hospital settings.

Diagnostic Laboratories: Diagnostic labs play a key role in providing accurate test results, especially for molecular diagnostics and advanced pathogen detection.

Research Institutions: The growing focus on research and development related to emerging infectious diseases has also led to a rise in the demand for monkeypox diagnostic tools in research institutions.

Regional Insights

The regional landscape of the monkeypox diagnosis market reflects the varying levels of disease prevalence and the investment in diagnostic infrastructure.

North America: Dominating the market, North America is expected to account for approximately 41% of the market share in 2024. The region's advanced healthcare infrastructure, high investment in R&D, and established diagnostic capabilities contribute to its leading position. The prevalence of monkeypox, coupled with rising public awareness and the adoption of preventive measures like vaccination, further strengthens the market in this region. The U.S., in particular, has seen a surge in government-funded programs to develop and distribute diagnostic tests.

Europe: Europe is also seeing growth, driven by the increasing awareness of monkeypox as a public health threat and the subsequent expansion of diagnostic facilities. Countries in Europe are actively integrating monkeypox tests into their national infectious disease programs, which is expected to propel the market forward.

Asia-Pacific: While the monkeypox diagnosis market is in its early stages in Asia-Pacific, the region presents substantial growth opportunities. Countries such as India and China, with large populations and emerging healthcare systems, are likely to experience increased demand for diagnostic tools as the disease's awareness spreads.

Latin America and Middle East & Africa: These regions are expected to have a slower adoption of monkeypox diagnostic tools due to infrastructural challenges and limited awareness, though efforts are underway to improve healthcare access.

Market Drivers

Several key factors are driving the growth of the monkeypox diagnosis market.

Increased Global Awareness and Surveillance: The 2022 and 2023 outbreaks highlighted the need for efficient surveillance systems and diagnostic tools to control the spread of monkeypox. Governments and international organizations, including the WHO, have emphasized the importance of monitoring outbreaks, which has led to an increased demand for monkeypox diagnostic tools globally.

Technological Advancements in Diagnostic Tools: Rapid technological innovations, such as real-time PCR and next-generation sequencing, have greatly improved the accuracy and speed of monkeypox testing. The development of point-of-care testing (POCT) solutions is also a major growth driver, enabling faster, on-site diagnosis, which is critical for timely outbreak containment.

Integration into Infectious Disease Panels: The integration of monkeypox testing into broader infectious disease panels is expanding the market. Healthcare providers now use multiplex testing platforms to detect various pathogens simultaneously, enhancing diagnostic efficiency and increasing demand for monkeypox diagnostic tools.

Market Restraints

Despite the promising growth, there are certain challenges that could hinder the market's expansion.

Limited Awareness and Testing Infrastructure in Developing Regions: Many developing countries still lack the necessary healthcare infrastructure and access to diagnostic tools, making it difficult to implement widespread testing. In regions with limited resources, testing for monkeypox may be deprioritized in favor of more prevalent diseases.

Regulatory Challenges: The approval process for diagnostic tests is often lengthy and costly, with different countries having varying regulatory requirements. These challenges could slow the market's growth as companies navigate complex regulatory landscapes.

Market Opportunities

The monkeypox diagnosis market offers significant growth opportunities for companies and stakeholders.

Expansion of Point-of-Care Testing: The increasing demand for rapid diagnostics, particularly in remote or resource-limited settings, presents a major opportunity for the development and expansion of point-of-care testing. This technology could significantly improve the speed and accuracy of diagnosis, enabling faster responses to outbreaks.

Emerging Markets: As monkeypox awareness grows globally, emerging markets are expected to see a rise in demand for diagnostic tools. Companies can tap into these markets by developing affordable and accessible diagnostic solutions tailored to regional healthcare needs.

Frequently Asked Questions (FAQs)

How Big is the Monkeypox (Mpox) Diagnosis Market?
Who are the Key Players in the Global Market for Monkeypox (Mpox) Diagnosis?
What is the Projected Growth Rate of the Monkeypox (Mpox) Diagnosis Market?
What is the Market Forecast for Monkeypox (Mpox) Diagnosis in 2031?
Which Region is Estimated to Dominate the Monkeypox (Mpox) Diagnosis Industry through the Forecast Period?

Company Insights

• Roche Diagnostics
• Abbott Laboratories
• Cepheid
• Thermo Fisher Scientific
• BioMérieux

Recent Developments
Roche Diagnostics launched a new PCR-based monkeypox testing solution aimed at improving diagnostic accuracy in decentralized settings.

Cepheid introduced a rapid molecular diagnostic test for monkeypox, allowing for faster detection and better outbreak management.

Conclusion

The monkeypox (mpox) diagnosis market is poised for steady growth, driven by technological advancements, increasing global awareness, and the ongoing need for accurate diagnostic solutions. North America will continue to lead the market, while regions such as Asia-Pacific and Latin America offer significant growth potential due to the expanding demand for diagnostic tools. As the market matures, the focus will likely shift towards more decentralized testing solutions, such as point-of-care testing, which could transform the way monkeypox and other infectious diseases are diagnosed.

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web:
https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.